Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Positron Emission Tomography (PET) Radiotracer Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The positron emission tomography (PET) radiotracer market has experienced robust growth recently. It is projected to increase from $2.54 billion in 2025 to $2.78 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. The historical expansion of this market can be attributed to several factors including rising cancer diagnosis rates, the proliferation of nuclear medicine facilities, the established application of FDG-based imaging, the availability of cyclotron infrastructure, and the general growth of diagnostic imaging services.
The positron emission tomography (pet) radiotracer market size is anticipated to experience substantial expansion in the coming years. It will grow to $3.95 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. This growth over the forecast period is propelled by a surge in demand for precision diagnostics, elevated capital expenditure in radiopharmaceutical research and development, the broadening scope of theranostics applications, the widening integration of PET imaging in neurological and cardiac fields, and more frequent regulatory clearances for novel tracers. Significant trends expected during this period include a rise in the creation of target-specific radiotracers, growing integration of PET imaging in oncology diagnostics, expanded utilization of novel isotopes beyond FDG, the enlargement of personalized nuclear medicine applications, and a greater emphasis on the production of short-half-life radiotracers.
Get A Free Sample Report With In-Depth Market Insights:
Positron Emission Tomography (PET) Radiotracer Market Growth Factors: What’s Supporting Expansion?
A surge in the occurrence of infectious diseases is anticipated to boost the expansion of the positron emission tomography (PET) radiotracer market in the future. These diseases are ailments resulting from harmful microorganisms like bacteria, viruses, fungi, or parasites. The increasing incidence of infectious diseases can be attributed to factors such as climate change, urbanization, globalization, resistance to antibiotics, and shifts in human behavior, all of which contribute to the wider dissemination of pathogens. Positron emission tomography (PET) radiotracers assist in addressing infectious diseases by allowing visualization of metabolic activity and inflammation, thereby facilitating the identification of infections, evaluating the effectiveness of treatment, and distinguishing between infectious and non-infectious conditions to enhance patient results. For instance, in February 2024, according to a report published by the UK Health Security Agency, a UK-based government agency, tuberculosis (TB) cases in England increased by 10.7% in 2023, with 4,850 cases reported compared to 4,380 in 2022. Consequently, the rising prevalence of infectious diseases is fueling the growth of the positron emission tomography (PET) radiotracer market.
Positron Emission Tomography (PET) Radiotracer Market Segment Breakdown: Which Categories Lead On Revenue?
The positron emission tomography (pet) radiotracer market covered in this report is segmented –
1) By Radiotracer Type: F-18 (Fluorodeoxyglucose 18), Ga-68 (Fibroblast Activation Protein Inhibitor), Other Radiotracer Types
2) By Application: Cancer, Heart Disease, Gastrointestinal, Endocrine, Neurological Disorders, Other Applications
3) By End-User: Hospitals, Diagnostic Centers, Other End-Users
Subsegments:
1) By F-18 (Fluorodeoxyglucose 18): F-18 FDG (Fluorodeoxyglucose), F-18 Fluoroethyltyrosine (FET), F-18 Florbetapir (Amyloid PET Imaging)
2) By Ga-68 (Fibroblast Activation Protein Inhibitor): Ga-68 Dotatate (Neuroendocrine Tumor Imaging), Ga-68 PSMA (Prostate-Specific Membrane Antigen Imaging), Ga-68 FAPI (Fibroblast Activation Protein Inhibitor Imaging)
3) By Other Radiotracer Types: C-11 (Carbon-11), N-13 (Nitrogen-13), O-15 (Oxygen-15), Rb-82 (Rubidium-82), I-124 (Iodine-124)
Positron Emission Tomography (PET) Radiotracer Market Industry Trends: What’s Reshaping Demand?
Leading companies operating in the positron emission tomography (PET) radiotracer market are concentrating on developing advanced diagnostic solutions, such as positron emission tomography imaging agents, to improve cancer detection and enhance patient outcomes. A positron emission tomography (PET) imaging agent refers to a radioactive substance employed to visualize and measure biological processes within the body during PET scans. For instance, in March 2023, IsoLogic Innovative Radiopharmaceuticals, a Canada-based radiopharmaceutical company, launched Illuccix, also known as the Ga-68 Gozetotide Preparation Kit (PSMA-11), in Canada. This product serves as a prostate cancer imaging agent specifically designed to detect metastatic prostate cancer. This tool proves valuable for physicians in identifying metastatic disease and supporting patient management decisions. It is indicated for use in patients suspected of having metastasis who are candidates for initial definitive therapy, and also in those with suspected recurrence indicated by elevated serum prostate-specific antigen (PSA) levels.
Positron Emission Tomography (PET) Radiotracer Market Key Participants And Competitive Landscape
Major companies operating in the positron emission tomography (pet) radiotracer market are Cardinal Health Inc., GE Healthcare Technologies Inc., Bracco Imaging S.p.A., Lantheus Holdings Inc., Jubilant Pharma Limited, SOFIE Biosciences, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Nordion Inc., Isologic Innovative Radiopharmaceuticals, ABX Advanced Biochemical Compounds GmbH, IBA Radiopharma Solutions S.A., ImaginAb Inc., Radiomedix Inc., Curium Pharma, Blue Earth Diagnostics Ltd., Eckert & Ziegler Radiopharma GmbH, Advanced Accelerator Applications (Novartis), Telix Pharmaceuticals Limited, PETNET Solutions Inc., Piramal Imaging
View The Full Positron Emission Tomography (PET) Radiotracer Market Report:
Positron Emission Tomography (PET) Radiotracer Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the positron emission tomography (PET) radiotracer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (pet) radiotracer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
